Citigroup’s Denali Therapeutics DNLI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$620K Buy
+30,000
New +$702K ﹤0.01% 3625
2026
Q2
– Sell
-30,000
Closed -$576K – 5847
2026
Q1
$576K Buy
+30,000
New +$597K ﹤0.01% 3461
2024
Q3
– Sell
-59,900
Closed -$1.39M – 5710
2024
Q2
$1.39M Buy
+59,900
New +$1.15M ﹤0.01% 2646

Other funds holding DNLI

Citigroup's DNLI Position: Q3 2026 in Review

Citigroup reduced its Denali Therapeutics (DNLI) stake by 32% in Q3 2026, selling an estimated $3.62M and leaving 332,788 shares worth $6.88M. The position accounts for ﹤0.01% of the portfolio, ranked #1894.

Citigroup first reported a position in DNLI in Q1 2018 and has held it in 35 quarters since. The position peaked at $12.5M in Q2 2026. 284 funds tracked by Wall St. Rank hold DNLI as of Q3 2026.

  • Citigroup held 332,788 shares of Denali Therapeutics worth $6.88M as of Q3 2026.
  • Citigroup sold 154,490 Denali Therapeutics shares in Q3 2026, an estimated $3.62M.
  • Denali Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q3 2026, its #1894 holding.
  • Citigroup first reported a position in Denali Therapeutics in Q1 2018 and has held it in 35 quarters since.
  • Citigroup's Denali Therapeutics position peaked at $12.5M in Q2 2026.
  • 284 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2026.

Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.